TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
This week, we will discuss intermittent hemodialysis versus continuous hemodialysis for AKI in the ICU (ICRAKI study)
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Welcome👋to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) September 28, 2023
"We seek it here,we seek it there.."
Aye,we nephrologists seek it everywhere.
Couple of weeks ago, NephJC discussed the intriguing urinary biomarker study for diagnosis of AIN by @dmoledina et al.
✳️#NephJC catch-up✳️of the damned, elusive chase!👇 pic.twitter.com/OsiMjOaKEA